



CONSULTING ACTUARIES & HEALTHCARE SPECIALISTS
Clearwater, FL • Louisville, KY • Denver, CO

**ARIZONA
HEALTH CARE COST CONTAINMENT SYSTEM
MEDICAID RISK ADJUSTMENT
WHITEPAPER**

Prepared by
Wakely Consulting Group

December 11, 2008
Update: June 30, 2009

AHCCCS MEDICAID RISK ADJUSTMENT

OVERVIEW

This whitepaper documents the risk adjustment approach to be implemented for the Arizona Medicaid program for the Contract Year Ending 2009 (CYE2009) rating period (October 2008 through September 2009). It should not be used for other purposes, including applying risk adjustment to other populations for which this methodology may not be appropriate. While the methodology presented in this document represents the methodology intended to be implemented for CYE2009, additional analysis is ongoing. Therefore, although there are no plans to amend, AHCCCS reserves the right to amend the methodology and this document to ensure that results are reasonable and the final rating approach for future contract periods is actuarially sound.

Risk adjustment of capitation payments modifies revenue to health plans based on the health status of their covered population relative to the average health status of the population. Since the Arizona Medicaid program is 100% managed care, the risk adjustment methodology will adjust payments among health plans and will be budget neutral to AHCCCS.

The Acute Care Services RFP for CYE2009 included the following language with respect to risk adjustment:

AHCCCS will be utilizing a national episodic/diagnostic risk adjustment model that will be applied to all Contractor specific capitation rates for all non-reconciled risk groups. Further methodology details will be shared with the Contractor prior to implementation.

Given anticipated membership changes that may be occurring due to the enhanced auto-assignment discussed in Section I Paragraph 9, Award of Contract, AHCCCS anticipates applying these risk factors by April 1, 2009 retroactively to the October 1, 2008, awarded capitation rates. For CYE 09, AHCCCS will apply approximately 80% of the capitation rate risk adjustment factor. Effective October 1, 2009, the full impact of the model will be applied.

The goals of risk adjustment in the context of the Arizona Medicaid program are as follows:

1. The model should move the program forward in terms of aligning payment with the relative health of members at each health plan.
2. The model and methodology should be accurate and unbiased.
3. The methodology should be as simple as possible while accomplishing these goals.
4. The administrative burden to develop and implement the methodology should be reasonable.
5. The results should be budget neutral to the program in total.

METHODOLOGY

The methodology used to develop the model, as well as the implementation approach, is documented below. Special considerations were made to risk adjust the TANF Under Age One risk group. The methodology for the TANF Under Age One risk group is provided in Appendix A.

Model / Vendor

AHCCCS has selected Symmetry's Episode Risk Groups (ERG) model. Episode Risk Groups (ERGs) is a risk assessment model developed by Symmetry Health Data Systems, a subsidiary of Ingenix, Inc. ERGs are based on the Episode Treatment Groups (ETGs) model, which groups medical services into episodes of care. The ERGs were developed and released in 2001. Those used in this analysis are based on Version 7.0 of the ETGs.

The ERG model assigns each member to one or more of the 167 ERGs based on diagnostic and procedural information available on medical and pharmacy claims. An ERG profile for each member is created by considering age, gender and the ERGs to which they have been assigned. A relative health status weight is associated with each age, gender and ERG category.

Type of Data

AHCCCS risk adjustment methodology uses diagnosis codes and procedural information from approved, adjudicated and paid medical data in addition to National Drug Codes (NDCs) from pharmacy data. Supplemental data is not included. This approach leverages strengths of pharmacy data while still allowing differentiation with the additional detail that diagnosis codes provide. The ERG model being used was developed consistent with this approach.

Symmetry provides updates to diagnosis codes and NDCs so that the mapping to ETGs and ERGs is as up to date as possible. AHCCCS will update the codes prior to each calibration and/or implementation of the model.

Time Periods for Data:

- Calibration for Preliminary Data
 - ERG /Age Gender Markers – May 2006 through April 2007
 - ETG – May 2004 through April 2007
 - Costs – June 2007 through May 2008
- Preliminary to health plans – June 2007 through May 2008 (“base” period), using October 1, 2008 enrollment (“projection” period)
- Calibration for Final Data
 - ETG /ERG /Age Gender Markers – October 2006 through September 2007
 - Costs – October 2007 through September 2008
- Final to health plans – October 2007 through September 2008 (“base” period), using October 2008 through March 2009 enrollment and 6 months using April 2009 enrollment (“projection” period)

Eligibility Groups

AHCCCS will risk adjust the prospective, non-reconciled risk groups (SSI with and without Medicare, TANF, and AHCCCS Care / Non-MED). The following rates will not have a claims based risk adjustment model applied:

1. Reconciled risk groups
2. Delivery supplemental rates
3. Option 1 & 2 transplant members
4. SOBRA Family Planning Rates

Model Calibration

The model was calibrated to the Arizona Medicaid population. The following costs will not be reflected in the condition or demographic weights in the calibrated model:

1. Prior Period Coverage (PPC)
2. Behavioral Health covered by Arizona Department of Health Services (ADHS)
3. Costs above reinsurance thresholds for which health plans were not at risk
4. Children’s Rehabilitative Services
5. Maternity costs covered by the Delivery Supplement

The diagnoses on all claims are used for purposes of identifying conditions, but the costs not at risk were excluded for purposes of determining the risk weights. This process captures the additional complexity / cost for at risk conditions due to the presence of an underlying not at risk (i.e. behavioral) condition.

While health plans have several options with respect to reinsurance thresholds, different risk weights for each of those thresholds were not developed. Reinsurance recoveries were excluded similarly for all health plan data according to the reinsurance thresholds in place during the experience period. This approach was a necessary simplification.

Adjustments for pharmacy rebates were made to the data prior to calibrating the risk weights.

Risk weights were developed by age/gender category and for all of the 167 ERG condition categories. Three sets of risk weights were developed for the 167 ERG condition categories (TANF <1 was handled separately – see Appendix A): 1) TANF and Non-MED, 2) SSI without Medicare, and 3) SSI with Medicare. Only members with at least six months of experience in the base period and one month of experience in the projection period were used in the calibration. Each member's contribution to the regression model and therefore the risk weights, was weighted according to the number of months that member was enrolled during the prospective period.

As is typical with risk adjustment calculations, the average ERG factors were not equal to the average age/gender factors for various sub-groups. This does not create a problem for the SSI without Medicare and SSI with Medicare risk groups since separate risk weights were developed for each. However, since only one set of risk weights was calculated for all of the risk groups within TANF and Non-MED categories, a 'scaling factor' adjustment was required. The scaling factor adjustment ensures that the average ERG factor for members who are assigned an ERG factor is equal to the average age/gender factor for the same cohort by risk group (statewide, not by GSA). The scaling factors by TANF risk group and for Non-MED are shown at the bottom of Exhibit B.

Geographic Issues

Model weights were based on statewide data. Risk adjustments will take place at the Geographical Service Area (GSA) and risk group level. For GSA 10 (Pima and Santa Cruz), two separate risk adjustment calculations will take place: 1) for health plans awarded both Pima and Santa Cruz, and 2) for health plans awarded only Pima.

Individual Approach

Risk scores calculated during the experience period will follow the individual during the rating period. This approach is most accurate in terms of reflecting changes in enrollment between the experience and rating periods and movement of individuals between health plans.

Member Inclusion and Risk Factors for New Members / Short Duration

Only members with at least six months of enrollment during the experience period ('long' cohort) will be given a claims based risk adjustment factor (average ERG risk score). Members with less than six months of enrollment during the experience period ('short' cohort) will be given a risk factor that is equal to 50% of their pure age/gender factor plus 50% of an adjusted plan factor. The adjusted plan factor is calculated by taking the average ERG risk score of the long cohort and dividing by the pure age/gender factor of the long cohort (relative health factor) and then multiplying by the pure/age gender factor of the short cohort.

As an example (also see Exhibit A – TANF 1-13), consider a health plan that has a long cohort average ERG risk score of 0.3910, a long cohort pure age/gender factor of 0.4000, and a short cohort pure age/gender factor of 0.4004. Further, assume that enrollment is split with 82% for the long cohort and 18% for the short cohort. The relevant values would be as follows:

Risk Adjustment Factor for Long Cohort = 0.3910

Risk Adjustment Calculation for the Short Cohort

Relative Health Factor = $0.3910 / 0.4000 = 0.9775$

Adjusted Plan Factor = $0.9775 \times 0.4004 = 0.3913$

Pure Age/Gender Factor = 0.4004

Risk Adjustment Factor = $50\% \times 0.3913 + 50\% \times 0.4004 = 0.3958$

Total Average Risk Score for the Health Plan = $82\% \times 0.3910 + 18\% \times 0.3958 = 0.3919$

Gaps in enrollment are ignored. Therefore, if a member was enrolled for four months, then disenrolled for two months and then reenrolled for five months, this member would be considered as having nine months of enrollment and thus would be assigned an ERG risk adjustment factor.

Phase-in

Per the RFP, 80% of the calculated adjustment will be applied. Therefore, if the risk adjustment factor for a particular health plan is 1.05 before phase-in, the risk adjustment factor after phase-in will be $1.04 = 1.05 \times 80\% + 1.00 \times 20\%$.

Encounter Data Validation and Issues

AHCCCS regularly performs testing on encounters to identify any potential areas of concern. If AHCCCS identifies an area where encounters are not being submitted, AHCCCS contacts the health plan and works with the health plan to improve encounter submissions. AHCCCS monitors the encounters by reviewing encounter data by date of service and form type to identify potential issues. In addition, AHCCCS compares the health plan's encounter data to their financials by quarter and compares how the health plans look relative to one another. Additional testing was performed for the risk adjustment process which includes, but is not limited to, reviewing the average number of encounters per member per month, the average number of diagnosis codes per encounter by form type by health plan, the portion of a health plan's population that has zero encounters and the portion of the population scored. These results are then compared across the health plans.

Risk Adjustment for Pima Health Plan Members

Based on the encounter analysis mentioned above, data for Pima Health Plan was not considered accurate and complete for the experience period of October 1, 2007 through September 30, 2008. Thus Pima Health Plan base period data will not be used for risk adjustment. Therefore, members enrolled in Pima Health Plan during the experience period will receive a pure age/gender factor unless they have sufficient experience in another health plan. Analysis of Pima Health Plan data for the period October 1, 2006 through September 30, 2007 (determined to be the most recent accurate and complete data) supports this methodology.

Due to applying the age/gender factor to Pima Health Plan members (enrolled in Pima Health Plan during the experience period), the short cohort group's percentage factor applied to the age/gender will no longer be 50%. The more Pima members a plan has in the short cohort, the higher the percentage that will be applied to the age/gender of the short cohort members. For example, if 80% of a plan's short cohort members were enrolled in Pima Health Plan during the experience period, the short cohort will have 90% $[(50\% \times 20\%) + (100\% \times 80\%) = 90\%]$ applied to the age/gender and 10% $[(50\% \times 20\%) + (0\% \times 80\%)]$ applied to the health status (i.e. plan factor). The long cohort will remain the same.

Data for all other health plans will be used for risk adjustment.

Reporting

AHCCCS will provide the following reports as part of the risk factor implementation. Each report represents a unique combination of health plan, risk group and GSA. Exhibits provided in this paper are only for the TANF 1-13 risk group and include mock data for illustration purposes only.

1. Exhibit A - Summary results showing the risk score adjustment.
2. Exhibit B – Detailed development of ERG risk scores for members who received a risk score.
3. Exhibit C – Age/Gender risk scores for all members.
4. Exhibit D – Risk adjusted capitation rate sheets.

Implementation

Risk adjustment factors will be applied retroactively to the October 1, 2008 contracted capitation rates less bid admin, bid risk contingency and premium tax. See Exhibit D for a sample of the rate sheet AHCCCS will provide to the health plans.

Exhibit A (TANF 1-13)
Summary Results
GSA X - MCO A

| Ref | Description | MCO A | All MCOs | Source |
|-----|---|--------|----------|--|
| A | Percentage of Members in the 'long' cohort ¹ | 82.00% | 80.00% | Enrollment during Oct. 2008 to April 2009 ² |
| B | Average ERG Risk Score for the long cohort | 0.4109 | 0.4023 | See Exhibit B |
| C | Average Pure Age/Gender Factor for the long cohort | 0.4034 | 0.4020 | See Exhibit C |
| D | Relative Health Factor ³ | 1.0184 | 1.0007 | D = B / C |
| E | Percentage of Members in the 'short' cohort ⁴ | 18.00% | 20.00% | E = 100% - A |
| F | Average Pure Age/Gender Factor for the short cohort | 0.4031 | 0.4013 | See Exhibit C |
| G | Adjusted Plan Factor applied to the short cohort ⁵ | 0.4105 | 0.4016 | G = D X F |
| H | Risk Factor for the short cohort | 0.4068 | 0.4014 | H = 50% x F + 50% x G |
| I | Total Average Risk Score | 0.4101 | 0.4021 | I = B x A + E x H |
| J | Relative Risk Score | 1.0200 | | J = I _{MCO} / I _{All MCOs} |
| K | Relative Risk Score with Phase In | 1.0160 | | K = 80% x J + 20% x 1.00 |
| L | Budget Neutrality Adjustment | 0.9998 | | Separate calculation |
| M | Risk Score Adjustment to Cap Rate | 1.0162 | | M = K / L |

Notes

- 1) This represents those members who have at least 6 months of eligibility during the experience period ('long' cohort).
- 2) Enrollment used is October 2008 to March 2009 weighted at 50% and April 2009 enrollment weighted at 50%.
- 3) This represents the "pure" health factor of the long cohort without any demographic impact. This factor is used to calculate the risk factor for the short cohort (those with less than 6 months of eligibility).
- 4) This represents those members who have less than 6 months of eligibility during the experience period ('short' cohort).
- 5) This represents the "plan factor" (ie risk score) for the short cohort. This takes into account the "pure" health status of the long cohort (assuming the short cohort's pure health status will look like the long), but using the short cohort demographics.

Exhibit B (TANF 1-13)
Detailed ERG Risk Scores for Members with Risk Score Assigned
GSA X - MCO A

| Ref | Short Description | Risk Weight | MCO A | | All MCOs Population | |
|--------------------|--|-------------|-----------|-------------------|---------------------|-------------------|
| | | | Frequency | Risk Contribution | Frequency | Risk Contribution |
| Demo1 ¹ | TANF 1-6 | 0.2190 | 56.00% | 0.1226 | 54.00% | 0.1182 |
| Demo2 ¹ | TANF 7-13 | 0.1751 | 44.00% | 0.0770 | 46.00% | 0.0805 |
| 1.011 | Lower cost inf dis | 0.0326 | 10.17% | 0.0033 | 9.56% | 0.0031 |
| 1.021 | Oth mod cost inf dis | 0.2550 | 0.19% | 0.0005 | 0.17% | 0.0004 |
| 1.031 | Non HIV maj inf dis I | 0.8735 | 0.15% | 0.0013 | 0.13% | 0.0012 |
| 1.032 | Non HIV maj inf dis II | 0.7066 | 0.28% | 0.0019 | 0.23% | 0.0016 |
| 1.033 | Non HIV maj inf dis III | 2.3151 | 0.02% | 0.0004 | 0.01% | 0.0003 |
| 1.034 | Non HIV maj inf dis w sig c/c | 0.0000 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 1.041 | AIDS/HIV | 3.6603 | 0.01% | 0.0002 | 0.01% | 0.0004 |
| 1.042 | AIDS/HIV w signif c/c | 5.6554 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 2.011 | Other low cost endocrinology | 0.0905 | 2.04% | 0.0018 | 2.04% | 0.0018 |
| 2.021 | Diabetes, wo signif c/c | 0.5801 | 0.01% | 0.0001 | 0.01% | 0.0001 |
| 2.022 | Diabetes, w signif c/c I | 1.0108 | 0.03% | 0.0003 | 0.04% | 0.0004 |
| 2.023 | Diabetes, w signif c/c II | 2.2389 | 0.08% | 0.0018 | 0.09% | 0.0020 |
| 2.031 | Hyperlipidemia, exc lipidoses | 0.1009 | 0.29% | 0.0003 | 0.28% | 0.0003 |
| 2.041 | Oth mod cost endocrinology | 0.2860 | 0.71% | 0.0020 | 0.71% | 0.0020 |
| 2.051 | Oth high cost endocrinology I | 1.2217 | 0.00% | 0.0001 | 0.00% | 0.0001 |
| 2.052 | Oth high cost endocrinology II | 1.5253 | 0.07% | 0.0011 | 0.07% | 0.0010 |
| 2.053 | Oth high cost endocrinology III | 2.0007 | 0.01% | 0.0003 | 0.02% | 0.0004 |
| 2.061 | Mal neo pancreas/pituitary/adrenal w am | 8.6885 | 0.00% | 0.0001 | 0.00% | 0.0001 |
| 2.071 | Mal neo thyroid & parathyroid w am | 0.7545 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 3.011 | Low cost hematology | 0.1084 | 1.59% | 0.0017 | 1.51% | 0.0016 |
| 3.021 | Oth mod cost hematology I | 1.1197 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 3.022 | Oth mod cost hematology II | 1.0807 | 0.03% | 0.0003 | 0.03% | 0.0004 |
| 3.031 | Neoplastic blood dis & Leukemia I | 1.2527 | 0.01% | 0.0002 | 0.01% | 0.0002 |
| 3.032 | Neoplastic blood dis & Leukemia II | 5.7181 | 0.00% | 0.0002 | 0.01% | 0.0003 |
| 3.033 | Neoplastic blood dis & Leukemia III | 10.0536 | 0.00% | 0.0003 | 0.00% | 0.0002 |
| 3.034 | Neoplastic blood dis & Leukemia IV | 17.8181 | 0.01% | 0.0017 | 0.01% | 0.0017 |
| 3.041 | Hemophilia | 9.9299 | 0.01% | 0.0008 | 0.01% | 0.0010 |
| 3.051 | Oth high cost hematology | 4.0707 | 0.01% | 0.0003 | 0.01% | 0.0003 |
| 3.061 | Sickle-cell anemia | 0.6036 | 0.02% | 0.0001 | 0.02% | 0.0001 |
| 4.011 | Low cost psychiatry | 0.1367 | 2.84% | 0.0039 | 3.09% | 0.0042 |
| 4.021 | Oth mod cost psychiatry | 0.1460 | 0.48% | 0.0007 | 0.46% | 0.0007 |
| 4.031 | Mood disorder, depress wo sig c/c | 0.2891 | 0.08% | 0.0002 | 0.10% | 0.0003 |
| 4.032 | Mood disorder, bipolar wo sig c/c | 0.2825 | 0.08% | 0.0002 | 0.09% | 0.0002 |
| 4.033 | Mood disorder, depress w sig c/c | 0.3218 | 0.12% | 0.0004 | 0.12% | 0.0004 |
| 4.034 | Mood disorder, bipolar w sig c/c | 0.3641 | 0.06% | 0.0002 | 0.05% | 0.0002 |
| 4.041 | Child psych disorders | 0.0296 | 4.71% | 0.0014 | 4.82% | 0.0014 |
| 4.051 | Psychotic & schizophrenic dis wo sig c/c | 0.3159 | 0.04% | 0.0001 | 0.03% | 0.0001 |
| 4.052 | Psychotic & schizophrenic dis w sig c/c | 0.0568 | 0.02% | 0.0000 | 0.01% | 0.0000 |
| 5.011 | Low cost substance abuse | 0.2304 | 0.06% | 0.0001 | 0.04% | 0.0001 |
| 5.021 | Mod/high cost substance abuse | 0.5029 | 0.06% | 0.0003 | 0.02% | 0.0001 |
| 6.011 | Oth low cost neurology | 0.1884 | 0.94% | 0.0018 | 0.87% | 0.0016 |
| 6.021 | Migraine wo signif c/c | 0.3424 | 0.23% | 0.0008 | 0.26% | 0.0009 |
| 6.022 | Migraine w signif c/c | 1.0065 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 6.031 | Oth mod cost neurology I | 0.3992 | 0.36% | 0.0014 | 0.37% | 0.0015 |
| 6.032 | Oth mod cost neurology II | 0.5279 | 0.23% | 0.0012 | 0.20% | 0.0011 |
| 6.041 | Oth high cost neurology I | 0.7320 | 0.14% | 0.0011 | 0.14% | 0.0011 |
| 6.042 | Oth high cost neurology II | 1.4352 | 0.04% | 0.0006 | 0.05% | 0.0007 |
| 6.051 | Epilepsy | 1.1196 | 0.21% | 0.0023 | 0.20% | 0.0023 |
| 6.061 | Multiple sclerosis & ALS | 0.9186 | 0.00% | 0.0000 | 0.01% | 0.0001 |
| 6.071 | Mal neo CNS wo metastases w am | 2.2776 | 0.01% | 0.0001 | 0.00% | 0.0001 |
| 6.072 | Mal neo CNS w metastases w am | 12.3618 | 0.00% | 0.0003 | 0.00% | 0.0002 |
| 7.011 | Oth low cost ophthalmology | 0.0302 | 14.25% | 0.0043 | 15.82% | 0.0048 |
| 7.021 | Mod cost ophthalmology | 0.6229 | 0.11% | 0.0007 | 0.11% | 0.0007 |
| 7.031 | Glaucoma | 0.2132 | 0.10% | 0.0002 | 0.08% | 0.0002 |

Exhibit B (TANF 1-13)
Detailed ERG Risk Scores for Members with Risk Score Assigned
GSA X - MCO A

| Ref | Short Description | Risk Weight | MCO A | | All MCOs Population | |
|--------|---------------------------------------|-------------|-----------|-------------------|---------------------|-------------------|
| | | | Frequency | Risk Contribution | Frequency | Risk Contribution |
| 7.041 | Cataract | 0.1849 | 0.05% | 0.0001 | 0.04% | 0.0001 |
| 7.051 | Diabetic retinopathy | 0.3634 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 7.061 | Mal neo of the eye | 0.3893 | 0.00% | 0.0000 | 0.01% | 0.0000 |
| 8.011 | Oth low cost cardiology I | 0.0604 | 1.06% | 0.0006 | 1.00% | 0.0006 |
| 8.012 | Oth low cost cardiology II | 0.3843 | 0.42% | 0.0016 | 0.38% | 0.0014 |
| 8.021 | Oth mod cost cardiology I | 0.3537 | 0.87% | 0.0031 | 0.80% | 0.0028 |
| 8.022 | Oth mod cost cardiology II | 0.9803 | 0.01% | 0.0001 | 0.01% | 0.0001 |
| 8.031 | Oth high cost cardiology I | 0.3118 | 0.04% | 0.0001 | 0.04% | 0.0001 |
| 8.041 | Isch hrt dis, CHF, cardiomyopathy I | 1.2743 | 0.00% | 0.0001 | 0.01% | 0.0001 |
| 8.042 | Isch hrt dis, CHF, cardiomyopathy II | 1.8964 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 8.043 | Isch hrt dis, CHF, cardiomyopathy III | 1.6225 | 0.01% | 0.0002 | 0.01% | 0.0002 |
| 8.044 | Isch hrt dis, CHF, cardiomyopathy IV | 2.4060 | 0.00% | 0.0001 | 0.00% | 0.0001 |
| 8.045 | Isch hrt dis, CHF, cardiomyopathy V | 1.6115 | 0.01% | 0.0001 | 0.01% | 0.0002 |
| 8.046 | Isch hrt dis, CHF, cardiomyopathy VI | 5.2042 | 0.01% | 0.0005 | 0.00% | 0.0002 |
| 8.051 | Hypertension wo c/c | 0.4493 | 0.08% | 0.0004 | 0.08% | 0.0003 |
| 8.052 | Hypertension w c/c | 1.0999 | 0.01% | 0.0001 | 0.01% | 0.0001 |
| 8.053 | Hypertension w sig c/c | 1.5237 | 0.01% | 0.0001 | 0.01% | 0.0001 |
| 8.061 | Heart/Lung Transplant | 27.6693 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 8.071 | Pulmonary hrt dis | 1.4835 | 0.02% | 0.0002 | 0.01% | 0.0002 |
| 9.011 | Oth low cost ENT I | 0.0522 | 53.02% | 0.0277 | 50.83% | 0.0266 |
| 9.012 | Oth low cost ENT II | 0.1104 | 8.75% | 0.0097 | 8.42% | 0.0093 |
| 9.021 | Oth mod cost ENT | 0.3278 | 1.00% | 0.0033 | 0.92% | 0.0030 |
| 9.031 | Mal neo ENT I | 3.0628 | 0.00% | 0.0001 | 0.00% | 0.0001 |
| 9.032 | Mal neo ENT II | 2.5629 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 10.011 | Oth low cost pulmonology I | 0.0765 | 3.73% | 0.0029 | 3.53% | 0.0027 |
| 10.012 | Oth low cost pulmonology II | 0.1822 | 1.30% | 0.0024 | 1.19% | 0.0022 |
| 10.021 | Oth mod cost pulmonology | 0.2865 | 1.01% | 0.0029 | 0.91% | 0.0026 |
| 10.031 | Acute bronchitis | 0.0960 | 7.01% | 0.0067 | 6.69% | 0.0064 |
| 10.041 | Asthma COPD I | 0.2239 | 4.85% | 0.0109 | 4.67% | 0.0105 |
| 10.042 | Asthma COPD II | 0.4006 | 4.30% | 0.0172 | 4.05% | 0.0162 |
| 10.043 | Asthma COPD III | 1.0698 | 0.33% | 0.0036 | 0.30% | 0.0032 |
| 10.044 | Asthma COPD IV | 3.0153 | 0.01% | 0.0004 | 0.01% | 0.0002 |
| 10.051 | Mal pulmonary neo wo am wo sig c/c | 3.2136 | 0.00% | 0.0001 | 0.01% | 0.0002 |
| 10.052 | Mal pulmonary neo wo am w sig c/c | 7.1875 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 10.053 | Mal pulmonary neo w am | 13.5639 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 10.061 | Oth high cost pulmonology I | 0.5364 | 0.25% | 0.0014 | 0.21% | 0.0011 |
| 10.062 | Oth high cost pulmonology II | 1.3220 | 0.11% | 0.0015 | 0.09% | 0.0012 |
| 11.011 | Oth low cost gastro I | 0.0878 | 13.31% | 0.0117 | 12.86% | 0.0113 |
| 11.012 | Oth low cost gastro II | 0.0596 | 0.13% | 0.0001 | 0.14% | 0.0001 |
| 11.013 | Oth low cost gastro III | 0.2818 | 3.52% | 0.0099 | 3.23% | 0.0091 |
| 11.021 | Oth mod cost gastro I | 0.9396 | 0.11% | 0.0011 | 0.09% | 0.0008 |
| 11.022 | Oth mod cost gastro II | 1.0091 | 0.20% | 0.0021 | 0.23% | 0.0023 |
| 11.031 | Hernias | 0.3099 | 0.41% | 0.0013 | 0.36% | 0.0011 |
| 11.041 | Oth high cost gastro I | 1.8931 | 0.02% | 0.0003 | 0.02% | 0.0004 |
| 11.042 | Oth high cost gastro II | 2.4677 | 0.00% | 0.0001 | 0.00% | 0.0001 |
| 11.051 | Mal neo gastro I | 1.1044 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 11.052 | Mal neo gastro II | 2.6506 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 11.053 | Mal neo gastro III | 10.8740 | 0.00% | 0.0000 | 0.00% | 0.0001 |
| 11.061 | Appendicitis | 0.0000 | 0.19% | 0.0000 | 0.21% | 0.0000 |
| 12.011 | Oth low cost hepatology I | 0.2216 | 0.10% | 0.0002 | 0.11% | 0.0002 |
| 12.012 | Oth low cost hepatology II | 0.7689 | 0.02% | 0.0002 | 0.02% | 0.0001 |
| 12.021 | Oth mod cost hepatology I | 0.2233 | 0.02% | 0.0001 | 0.03% | 0.0001 |
| 12.022 | Oth mod cost hepatology II | 0.6228 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 12.031 | Oth high cost hepatology | 1.6894 | 0.01% | 0.0001 | 0.01% | 0.0002 |
| 12.041 | Liver transplant | 6.5279 | 0.00% | 0.0001 | 0.00% | 0.0001 |
| 12.051 | Mal neo hepatobiliary system | 8.2657 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 13.011 | Low cost nephrology | 0.2731 | 0.10% | 0.0003 | 0.09% | 0.0003 |

Exhibit B (TANF 1-13)
Detailed ERG Risk Scores for Members with Risk Score Assigned
GSA X - MCO A

| Ref | Short Description | Risk Weight | MCO A | | All MCOs Population | |
|--------|--|-------------|-----------|-------------------|---------------------|-------------------|
| | | | Frequency | Risk Contribution | Frequency | Risk Contribution |
| 13.021 | Mod cost nephrology | 0.5155 | 0.02% | 0.0001 | 0.02% | 0.0001 |
| 13.031 | Kidney Transplant | 2.8855 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 13.041 | Chronic renal failure I | 0.4293 | 0.01% | 0.0000 | 0.01% | 0.0000 |
| 13.042 | Chronic renal failure II | 1.3575 | 0.00% | 0.0000 | 0.01% | 0.0001 |
| 13.043 | Chronic renal failure III | 3.9645 | 0.00% | 0.0001 | 0.00% | 0.0001 |
| 13.051 | Acute renal failure | 1.1478 | 0.01% | 0.0001 | 0.01% | 0.0001 |
| 14.011 | Low cost urology I | 0.1035 | 6.04% | 0.0063 | 5.72% | 0.0059 |
| 14.012 | Low cost urology II | 0.3370 | 0.58% | 0.0019 | 0.53% | 0.0018 |
| 14.021 | Mod cost urology | 0.6019 | 0.35% | 0.0021 | 0.34% | 0.0021 |
| 14.031 | Mal neo urology I | 1.8931 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 14.032 | Mal neo urology II | 0.7258 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 14.033 | Mal neo urology III | 1.2276 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 14.034 | Mal neo urology IV | 3.1017 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 15.011 | Normal pregnancy, delivery I | 0.0459 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 15.012 | Normal pregnancy, delivery II | 0.2044 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 15.021 | Normal pregnancy, non-delivery | 1.9701 | 0.00% | 0.0001 | 0.00% | 0.0001 |
| 15.031 | Oth mod cost obstetrics | 0.6055 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 16.011 | Oth low cost gynecology I | 0.1046 | 1.15% | 0.0012 | 1.06% | 0.0011 |
| 16.012 | Oth low cost gynecology II | 0.2134 | 0.17% | 0.0004 | 0.19% | 0.0004 |
| 16.021 | Oth mod cost gynecology I | 0.3579 | 0.00% | 0.0000 | 0.01% | 0.0000 |
| 16.022 | Oth mod cost gynecology II | 0.4784 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 16.031 | Mal neo brst/fem gen w am w sig c/c | 10.2093 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 16.032 | Mal neo brst/fem gen w am wo sig c/c I | 4.9572 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 16.033 | Mal neo brst/fem gen w am wo sig c/c II | 4.2215 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 16.034 | Mal neo brst/fem gen wo am w sig c/c | 2.1296 | 0.00% | 0.0001 | 0.00% | 0.0001 |
| 16.035 | Mal neo brst/fem gen wo am wo sig c/c I | 0.2516 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 16.036 | Mal neo brst/fem gen wo am wo sig c/c II | 1.9851 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 17.011 | Low cost dermatology I | 0.0352 | 26.84% | 0.0094 | 25.74% | 0.0091 |
| 17.012 | Low cost dermatology II | 0.2772 | 1.40% | 0.0039 | 1.26% | 0.0035 |
| 17.021 | Mod cost dermatology I | 0.9439 | 0.05% | 0.0005 | 0.06% | 0.0005 |
| 17.022 | Mod cost dermatology II | 1.5126 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 17.031 | High cost dermatology | 6.9101 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 18.011 | Oth low cost orthopedic I | 0.1694 | 2.09% | 0.0035 | 2.10% | 0.0036 |
| 18.012 | Oth low cost orthopedic II | 0.1862 | 1.42% | 0.0026 | 1.37% | 0.0026 |
| 18.021 | Orthopedic trauma, fract, disloc I | 0.1976 | 2.96% | 0.0059 | 3.09% | 0.0061 |
| 18.022 | Orthopedic trauma, fract, disloc II | 0.3408 | 0.89% | 0.0030 | 0.94% | 0.0032 |
| 18.023 | Orthopedic trauma, fract, disloc III | 0.8200 | 0.10% | 0.0008 | 0.12% | 0.0009 |
| 18.024 | Orthopedic trauma, fract, disloc IV | 1.2259 | 0.01% | 0.0002 | 0.01% | 0.0002 |
| 18.031 | Joint degen & major inflam I | 0.4466 | 0.33% | 0.0015 | 0.32% | 0.0014 |
| 18.032 | Joint degen & major inflam II | 1.0710 | 0.03% | 0.0004 | 0.03% | 0.0003 |
| 18.033 | Joint degen & major inflam III | 1.7107 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 18.041 | Oth high cost ortho I | 0.8316 | 0.03% | 0.0002 | 0.03% | 0.0002 |
| 18.042 | Oth high cost ortho II | 1.3752 | 0.03% | 0.0004 | 0.03% | 0.0004 |
| 18.051 | Adult rheumatoid arthritis | 0.7165 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 18.061 | Mal neo bone & connect tiss I | 2.2959 | 0.00% | 0.0001 | 0.01% | 0.0001 |
| 18.062 | Mal neo bone & connect tiss II | 1.5992 | 0.00% | 0.0000 | 0.00% | 0.0000 |
| 19.011 | Oth neonatal I | 0.0398 | 2.56% | 0.0010 | 2.48% | 0.0010 |
| 19.012 | Oth neonatal II | 0.2030 | 3.17% | 0.0064 | 2.92% | 0.0059 |
| 19.021 | High cost neonatal | 1.4391 | 0.04% | 0.0006 | 0.04% | 0.0005 |
| 21.011 | Late effects & complications | 0.9779 | 0.22% | 0.0022 | 0.20% | 0.0019 |
| 21.021 | Environmental trauma | 0.0748 | 1.29% | 0.0010 | 1.29% | 0.0010 |
| 21.031 | Poison & toxic effects of drugs I | 0.1008 | 0.53% | 0.0005 | 0.53% | 0.0005 |
| 21.032 | Poison & toxic effects of drugs II | 0.1480 | 0.05% | 0.0001 | 0.04% | 0.0001 |
| 21.033 | Poisoning & toxic effects of drugs III | 0.6882 | 0.01% | 0.0001 | 0.01% | 0.0001 |
| 22.011 | Isolated signs and symptoms | 0.0629 | 5.49% | 0.0035 | 5.52% | 0.0035 |
| RX.011 | High cost pharmacy only | 5.1798 | 0.00% | 0.0002 | 0.00% | 0.0001 |

Exhibit B (TANF 1-13)
Detailed ERG Risk Scores for Members with Risk Score Assigned
GSA X - MCO A

| Ref | Short Description | Risk Weight | MCO A | | All MCOs Population | |
|-----------------------------|-------------------|-------------|-----------|-------------------|---------------------|-------------------|
| | | | Frequency | Risk Contribution | Frequency | Risk Contribution |
| Unadjusted | | | | 0.4291 | | 0.4201 |
| Scaling Factor ² | | | | 1.0443 | | 1.0443 |
| Final Adjusted | | | | 0.4109 | | 0.4023 |

Notes

- 1) Demographic factors represent the demographic factors to be used in the ERG risk score and are not the pure age/gender factors.
- 2) The scaling factor ensures that the average ERG factor for the 'Long' cohort is equal to the average demographic factor for the 'Long' cohort by risk group.

| Exhibit C | | | | | | |
|--------------------------------------|-------------------|--------------|---------------|---------------|---------------|---------------|
| Age/Gender Risk Scores for TANF 1-13 | | | | | | |
| GSA X - MCO A | | | | | | |
| Ref | Short Description | Demo Weights | Short Cohort | | Long Cohort | |
| | | | Frequency | | Frequency | |
| | | | MCO A | All MCOs | MCO A | All MCOs |
| Demo1 | TANF 1-6 | 0.4350 | 55.50% | 53.00% | 56.00% | 54.00% |
| Demo2 | TANF 7-13 | 0.3633 | 44.50% | 47.00% | 44.00% | 46.00% |
| Total | | | 0.4031 | 0.4013 | 0.4034 | 0.4020 |

Exhibit D - Oct Cap

| Exhibit D MCO A GSA X Prospective Risk Groups to be Adjusted | | | | | | | | |
|--|-------------------|--------------------|--------------------------|--------------------------|---------------------|-----------------|------------------|-----------|
| PMPNs | TANF & KC < 1 M&F | TANF & KC 1-13 M&F | TANF & KC & HIFA 14-44 F | TANF & KC & HIFA 14-44 M | TANF & HIFA 45+ M&F | SSI w/ Medicare | SSI w/o Medicare | NotMED |
| 10-01-08 Capitation Rate ¹ | \$400.00 | \$100.00 | \$200.00 | \$100.00 | \$400.00 | \$150.00 | \$700.00 | \$500.00 |
| Less Bid Risk Contingency | (\$8.00) | (\$2.00) | (\$4.00) | (\$2.00) | (\$8.00) | (\$3.00) | (\$14.00) | (\$10.00) |
| Less Bid Admin | (\$32.00) | (\$8.00) | (\$16.00) | (\$8.00) | (\$32.00) | (\$12.00) | (\$56.00) | (\$40.00) |
| Less Premium Tax | (\$8.00) | (\$2.00) | (\$4.00) | (\$2.00) | (\$8.00) | (\$3.00) | (\$14.00) | (\$10.00) |
| Cap Rate to be Risk Adjusted (a) | \$352.00 | \$88.00 | \$176.00 | \$88.00 | \$352.00 | \$132.00 | \$616.00 | \$440.00 |
| Risk Adjustment Factor (b) | 1.0078 | 1.0162 | 0.9884 | 1.0284 | 1.0234 | 1.0134 | 1.0090 | 0.9974 |
| Risk Adjusted Capitation Rate (a * b) | \$354.75 | \$89.42 | \$173.96 | \$90.50 | \$360.24 | \$133.77 | \$621.54 | \$438.86 |
| Plus Bid Risk Contingency | \$8.00 | \$2.00 | \$4.00 | \$2.00 | \$8.00 | \$3.00 | \$14.00 | \$10.00 |
| Plus Bid Admin | \$32.00 | \$8.00 | \$16.00 | \$8.00 | \$32.00 | \$12.00 | \$56.00 | \$40.00 |
| Plus Premium Tax | \$8.06 | \$2.03 | \$3.96 | \$2.05 | \$8.17 | \$3.04 | \$14.11 | \$9.98 |
| Risk Adjusted Capitation Rate | \$402.81 | \$101.45 | \$197.92 | \$102.55 | \$408.40 | \$151.80 | \$705.66 | \$498.83 |

Comments

1) Contracted Rate for CYE09 prior to risk adjustment.

Exhibit D - May Cap

| Exhibit D MCO A GSA X Prospective Risk Groups to be Adjusted | | | | | | | | |
|--|-------------------|--------------------|-------------------------------|-------------------------------|------------------------|-----------------|------------------|-----------|
| PMPMs | TANF & KC < 1 M&F | TANF & KC 1-13 M&F | TANF & KC & HIFA 14 - 44 F | TANF & KC & HIFA 44 - 44 M | TANF & HIFA 45+ M&F | SSI w/ Medicare | SSI w/o Medicare | NonMED |
| 05-01-09 Capitation Rate ¹ | \$395.00 | \$95.00 | \$195.00 | \$95.00 | \$395.00 | \$145.00 | \$695.00 | \$495.00 |
| Less Bid Risk Contingency | (\$8.00) | (\$2.00) | (\$4.00) | (\$2.00) | (\$8.00) | (\$3.00) | (\$14.00) | (\$10.00) |
| Less Bid Admin | (\$32.00) | (\$8.00) | (\$16.00) | (\$8.00) | (\$32.00) | (\$12.00) | (\$56.00) | (\$40.00) |
| Less Premium Tax | (\$7.90) | (\$1.90) | (\$3.90) | (\$1.90) | (\$7.90) | (\$2.90) | (\$13.90) | (\$9.90) |
| Cap Rate to be Risk Adjusted (a) | \$347.10 | \$83.10 | \$171.10 | \$83.10 | \$347.10 | \$127.10 | \$611.10 | \$435.10 |
| Risk Adjustment Factor (b) | 1.0078 | 1.0162 | 0.9884 | 1.0284 | 1.0234 | 1.0134 | 1.0090 | 0.9974 |
| Risk Adjusted Capitation Rate (a * b) | \$349.82 | \$84.44 | \$169.12 | \$85.46 | \$355.22 | \$128.80 | \$616.60 | \$433.97 |
| Plus Bid Risk Contingency | \$8.00 | \$2.00 | \$4.00 | \$2.00 | \$8.00 | \$3.00 | \$14.00 | \$10.00 |
| Plus Bid Admin | \$32.00 | \$8.00 | \$16.00 | \$8.00 | \$32.00 | \$12.00 | \$56.00 | \$40.00 |
| Plus Premium Tax | \$7.96 | \$1.93 | \$3.86 | \$1.95 | \$8.07 | \$2.93 | \$14.01 | \$9.88 |
| Risk Adjusted Capitation Rate | \$397.77 | \$96.37 | \$192.97 | \$97.41 | \$403.29 | \$146.74 | \$700.61 | \$493.85 |

Comments

1) Contracted Rate for CYE09 prior to risk adjustment, but after the physician fee schedule adjustment

APPENDIX A

Risk Adjustment for TANF Under Age One Year

Overview

Risk adjustment for TANF under age one (newborns) is necessarily different than risk adjustment for other risk groups. Instead of an individual approach where risk adjustment factors follow individual members, an aggregate, concurrent approach will be used. This approach assumes that historic relationships in newborn risk will continue into the future. While the specific newborns in any health plan will change from the experience period to the rating period, this approach assumes that health plans attract newborns with a consistent health status mix. Therefore, the goal of the TANF under age one risk adjustment methodology is to estimate differences in health status during the experience period.

Exhibits A and B show sample TANF Under Age One risk adjustment calculations. Exhibit C shows the risk markers used to differentiate risk and their respective diagnosis codes.

Model Development

Based on Arizona data for the newborn Medicaid populations, we identified a series of conditions that resulted in material variations among newborns due to the frequency, cost and nature of those conditions. We identified 11 general risk marker categories to differentiate the health and therefore risk of newborns (see Exhibit C).

Data used to identify the 11 risk markers was provided by AHCCCS and represented all claims data incurred between October 2006 and September 2008 for infants born from October 2006 through September 2007. We limited the analysis to the newborns that were enrolled and at risk to a health plan at the time of birth during this 12-month time period and therefore excluded those enrolled with PPC. In order to obtain a significant experience period for each newborn while also making sure to include major conditions, we only included newborns enrolled in the experience period for at least the first three months of life by any combination of health plans, or who died while enrolled in the program. These criteria resulted in a risk score calibration cohort of approximately 43,600 newborns.

Claims incurred within the first 12 months of life were analyzed for the newborns meeting these criteria. All claims were trended to the same point in time at an annualized rate of 5%. Members were identified as having a particular risk marker if any of the member's claims within the experience period contained the corresponding diagnosis codes in any of the diagnosis fields.

APPENDIX A

Risk Adjustment for TANF Under Age One Year

Calibration of weights for the 11 selected newborn risk markers was based on a concurrent, rather than prospective, methodology. Reinsurance recoveries were excluded from the risk weight calibration. Claims were also reduced for average pharmacy rebates.

The resulting weights for the 11 newborn risk markers are displayed in the Newborn Exhibit B.

Implementation

The TANF Under Age One risk adjustment methodology assigns a risk score to each health plan during the rating period based on diagnosis codes and the membership cohort enrolled at each health plan during the experience period.

Members with sufficient experience are identified during the experience period (October 2007 through September 2008). Sufficient experience is defined as being born in the period, with at least three months of enrollment if deceased or disenrolled during the period. Members with sufficient experience are assigned a risk score. An average risk score across all members who are assigned a risk score is developed.

The calculation of the average risk score for newborns who meet the enrollment criteria differs for health plans that are new to a GSA versus existing health plans. This methodology also affects risk scores for existing health plans in GSAs where new plans are entering (all but GSA 12).

The average GSA risk score calculated using all prior health plans' experience is the risk score assigned to health plans new to a GSA. The average GSA risk score is then recalculated using the actual risk scores for existing plans, the risk score assigned to the new plans (described above) and updated enrollment weights by health plan based on October 2008 through March 2009 enrollment and 6 months using April 2009 enrollment. This updated GSA average is used to calculate the relative risk scores for new and existing health plans for newborns that meet the enrollment criteria. This approach recognizes the uncertainty associated with new health plans entering a GSA, and lessens the impact of risk adjustment accordingly.

APPENDIX A

Risk Adjustment for TANF Under Age One Year

The following table shows a simple example of the risk score calculation for members meeting the enrollment criteria where MCO C is replacing MCO A:

| MCO | Historic Enrollment Weight | Risk Score | Oct/Nov 2008 Enrollment Weight | Risk Score | Relative Risk Adjustment |
|-------|----------------------------|------------|--------------------------------|------------|--------------------------|
| MCO A | 50.0% | 1.0500 | 0.0% | | |
| MCO B | 50.0% | 0.9500 | 60.0% | 0.9500 | 0.9794 |
| MCO C | 0.0% | | 40.0% | 1.0000 | 1.0309 |
| Total | 100.0% | 1.0000 | 100.0% | 0.9700 | 1.0000 |

MCO C receives the average GSA risk score of 1.000 in this simplified example. After this assignment and applying updated enrollment weights, the recalculated GSA average is 0.97. Finally, initial risk scores are divided by 0.97 to calculate relative risk adjustment factors.

Newborns not meeting the enrollment criteria described above are assigned 50% of the average relative risk adjustment for those meeting the eligibility criteria and 50% of a 1.00 factor. For example, if the average relative risk factor for members meeting the enrollment criteria is 1.05 (relative to GSA average), then the risk factor for members not meeting the enrollment criteria would be 1.025. Each health plan's risk score for newborns within a GSA will be calculated as the weighted average of the risk scores for newborns who met the above eligibility criteria during the experience period and those who did not.

Consistent with risk adjustment for other risk groups, the final risk adjustment factor is adjusted for 80% phase-in and budget neutrality.

Because both health plans in GSA 6 will be new to that area effective October 2008, both health plans will receive 1.000 risk scores for all TANF members less than one year of age.

GSA 10 will be treated as one GSA rather than as two separate GSAs (i.e. for health plans awarded Pima and Santa Cruz, versus those awarded Pima only).

AHCCCS will provide the following reports as part of the risk factor implementation (examples included as Exhibits). Each report represents a unique combination of health plan, risk group and GSA.

1. Exhibit A - Summary results showing the risk score adjustment at the health plan and GSA level.
2. Exhibit B - Detailed development of risk scores for members who received a risk score.

| Exhibit A Summary Results TANF <1 GSA X | | | | |
|---|--|--------|----------|---|
| Ref | Description | MCO A | All MCOs | Source |
| A | Percentage of Members w/ Risk Score ¹ | 40.00% | 38.00% | % enrolled at birth and at least 3 months |
| B | Average Risk Score ² | 1.0643 | 1.0536 | See Exhibit B |
| C | Updated avg. w/ new plan(s) at GSA avg. and updated mix ³ | | 1.0500 | Separate Calculation |
| D | Relative Risk Score | 1.0136 | | D = B / C |
| E | Percentage of Members w/out Risk Score | 60.00% | | E = 100% - A |
| F | Risk Score for Members w/out Risk Score ⁴ | 1.0068 | | F = D x 50% + 1.00 x 50% |
| G | Total Average Risk Score | 1.0095 | | G = A x D + E x F |
| H | Relative Risk Score with Phase In | 1.0076 | | H = 80% x G + 20% x 1.00 |
| I | Budget Neutrality Adjustment | 0.9998 | | Separate calculation |
| J | Risk Score Adjustment to Cap Rate | 1.0078 | | J = H / I |

Notes

- 1) This represents newborns who were enrolled at birth and remain enrolled for at least 3 months during the experience period. GSA average for new plans.
- 2) For existing plans, enrollment used is October 2007 - September 2008. Health plans new to a GSA are assigned the prior average GSA risk score.
- 3) Health plans new to a GSA in CYE 2009 are assigned the prior average GSA risk score. This, coupled with enrollment changes, causes the updated GSA average risk score to change.
- 4) The population that does not meet the enrollment criteria receives a risk score that is 50% of the risk score for the cohort meeting the criteria plus 50% of a 1.000 factor

Appendix A
Risk Adjustment for TANF Under Age One Year

| Exhibit B Detailed Risk Scores for Members with Risk Score Assigned TANF <1 GSA X | | | | | | |
|---|---|-------------|-----------|-------------------|---------------------|-------------------|
| Ref. | Short Description | Risk Weight | MCO A | | All MCOs Population | |
| | | | Frequency | Risk Contribution | Frequency | Risk Contribution |
| Base | Base | 0.4957 | 100.00% | 0.4957 | 100.00% | 0.4957 |
| Risk 1 | Weight is less than 1500 grams | 4.0974 | 1.66% | 0.0680 | 1.50% | 0.0613 |
| Risk 2 | Weight is 1500 - 2499 grams | 0.8272 | 4.59% | 0.0379 | 4.29% | 0.0355 |
| Risk 3 | Septicemia | 1.4090 | 4.64% | 0.0654 | 4.48% | 0.0631 |
| Risk 4 | 29-32 Completed Weeks of Gestation | 2.3161 | 1.56% | 0.0360 | 1.54% | 0.0357 |
| Risk 5 | Less than 29 Completed Weeks of Gestation | 7.7844 | 0.52% | 0.0403 | 0.56% | 0.0437 |
| Risk 6 | Respiratory Distress Syndrome and other Respiratory | 1.3457 | 8.91% | 0.1199 | 8.72% | 0.1173 |
| Risk 7 | Device Implants | 14.1494 | 0.30% | 0.0430 | 0.27% | 0.0388 |
| Risk 8 | Subdural or Subarachnoid Hemorrhage | 2.6589 | 0.14% | 0.0038 | 0.19% | 0.0050 |
| Risk 9 | Cardiac Congenital Disorders | 1.7919 | 5.55% | 0.0995 | 5.58% | 0.0999 |
| Risk 10 | Central Nervous System Congenital Disorders | 2.4815 | 1.19% | 0.0295 | 1.14% | 0.0282 |
| Risk 11 | Congenital Anomalies of Intestines & Abdomen | 5.8738 | 0.43% | 0.0254 | 0.50% | 0.0295 |
| Grand Total | | | | 1.0643 | | 1.0536 |

Appendix A
Risk Adjustment for TANF Under Age One Year

| Exhibit C TANF - Risk Marker Diagnosis Codes | | | |
|---|--------------------------------|----------------|--|
| Risk Group (See Exhibit B) | Risk/Marker Description | Diagnosis Code | ICD9 Description |
| 1 | Weight is less than 1500 grams | 764.94 | FETAL GROWTH RETARDATION, UNSPECIFIED, 1,000-1,249 GRAMS |
| 1 | Weight is less than 1500 grams | 765.13 | OTHER PRETERM INFANTS, 750-999 GRAMS |
| 1 | Weight is less than 1500 grams | 765.05 | EXTREME IMMATUREITY, 1,250-1,499 GRAMS |
| 1 | Weight is less than 1500 grams | 765.11 | OTHER PRETERM INFANTS, LESS THAN 500 GRAMS |
| 1 | Weight is less than 1500 grams | 765.14 | OTHER PRETERM INFANTS, 1,000-1,249 GRAMS |
| 1 | Weight is less than 1500 grams | 764.93 | FETAL GROWTH RETARDATION, UNSPECIFIED, 750-999 GRAMS |
| 1 | Weight is less than 1500 grams | 765.02 | EXTREME IMMATUREITY, 500-749 GRAMS |
| 1 | Weight is less than 1500 grams | 765.15 | OTHER PRETERM INFANTS, 1,250-1,499 GRAMS |
| 1 | Weight is less than 1500 grams | 765.03 | EXTREME IMMATUREITY, 750-999 GRAMS |
| 1 | Weight is less than 1500 grams | 765.12 | OTHER PRETERM INFANTS, 500-749 GRAMS |
| 1 | Weight is less than 1500 grams | 764.04 | "LIGHT-FOR-DATES" WITHOUT MENTION OF FETAL MALNUTRITION, 1,000-1,249 GRAMS |
| 1 | Weight is less than 1500 grams | 764.95 | FETAL GROWTH RETARDATION, UNSPECIFIED, 1,250-1,499 GRAMS |
| 1 | Weight is less than 1500 grams | 764.05 | "LIGHT-FOR-DATES" WITHOUT MENTION OF FETAL MALNUTRITION, 1,250-1,499 GRAMS |
| 1 | Weight is less than 1500 grams | 765.01 | EXTREME IMMATUREITY, LESS THAN 500 GRAMS |
| 1 | Weight is less than 1500 grams | 765.04 | EXTREME IMMATUREITY, 1,000-1,249 GRAMS |
| 2 | Weight is 1500 - 2499 grams | 765.16 | OTHER PRETERM INFANTS, 1,500-1,749 GRAMS |
| 2 | Weight is 1500 - 2499 grams | 765.17 | OTHER PRETERM INFANTS, 1,750-1,999 GRAMS |
| 2 | Weight is 1500 - 2499 grams | 764.06 | "LIGHT-FOR-DATES" WITHOUT MENTION OF FETAL MALNUTRITION, 1,500-1,749 |
| 2 | Weight is 1500 - 2499 grams | 764.96 | FETAL GROWTH RETARDATION, UNSPECIFIED, 1,500-1,749 GRAMS |
| 2 | Weight is 1500 - 2499 grams | 765.18 | OTHER PRETERM INFANTS, 2,000-2,499 GRAMS |
| 2 | Weight is 1500 - 2499 grams | 764.98 | FETAL GROWTH RETARDATION, UNSPECIFIED, 2,000-2,499 GRAMS |
| 2 | Weight is 1500 - 2499 grams | 764.97 | FETAL GROWTH RETARDATION, UNSPECIFIED, 1,750-1,999 GRAMS |
| 2 | Weight is 1500 - 2499 grams | V 2135 | LOW BIRTH WEIGHT STATUS, 2000-2500 GRAMS |
| 2 | Weight is 1500 - 2499 grams | V 2134 | LOW BIRTH WEIGHT STATUS, 1500-1999 GRAMS |
| 2 | Weight is 1500 - 2499 grams | 765.07 | EXTREME IMMATUREITY, 1,750-1,999 GRAMS |
| 2 | Weight is 1500 - 2499 grams | 764.27 | FETAL MALNUTRITION WITHOUT MENTION OF "LIGHT-FOR-DATES", 1,750-1,999 GRAMS |
| 2 | Weight is 1500 - 2499 grams | 765.06 | EXTREME IMMATUREITY, 1,500-1,749 GRAMS |
| 2 | Weight is 1500 - 2499 grams | 764.07 | "LIGHT-FOR-DATES" WITHOUT MENTION OF FETAL MALNUTRITION, 1,750-1,999 GRAMS |
| 2 | Weight is 1500 - 2499 grams | 765.08 | EXTREME IMMATUREITY, 2,000-2,499 GRAMS |
| 2 | Weight is 1500 - 2499 grams | 764.28 | FETAL MALNUTRITION WITHOUT MENTION OF "LIGHT-FOR-DATES", 2,000-2,499 GRAMS |
| 2 | Weight is 1500 - 2499 grams | 764.17 | "LIGHT-FOR-DATES" WITH SIGNS OF FETAL MALNUTRITION, 1,750-1,999 GRAMS |
| 3 | Septicemia | 038.40 | SEPTICEMIA DUE TO GRAM-NEGATIVE ORGANISM, UNSPECIFIED |
| 3 | Septicemia | 038.0 | STREPTOCOCCAL SEPTICEMIA |
| 3 | Septicemia | 038.42 | SEPTICEMIA DUE TO ESCHERICHIA COLI +E. COLI+ |
| 3 | Septicemia | 038.41 | SEPTICEMIA DUE TO HEMOPHILUS INFLUENZAE +H. INFLUENZAE+ |
| 3 | Septicemia | 771.81 | SEPTICEMIA +SEPSIS+ OF NEWBORN |
| 3 | Septicemia | 038.49 | OTHER SEPTICEMIA DUE TO GRAM-NEGATIVE ORGANISMS |
| 3 | Septicemia | 038.11 | METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS SEPTICEMIA |

Appendix A
Risk Adjustment for TANF Under Age One Year

| Exhibit C | | | | |
|------------------------------------|---|----------------|---|--|
| TANF - Risk Marker Diagnosis Codes | | | | |
| Risk Group (See Exhibit B) | Risk Marker Description | Diagnosis Code | ICD9 Description | |
| 3 | Septicemia | 038.9 | UNSPECIFIED SEPTICEMIA | |
| 3 | Septicemia | 038.2 | PNEUMOCOCCAL SEPTICEMIA | |
| 3 | Septicemia | 038.8 | OTHER SPECIFIED SEPTICEMIAS | |
| 3 | Septicemia | 038.44 | SEPTICEMIA DUE TO SERRATIA | |
| 3 | Septicemia | 038.10 | STAPHYLOCOCCAL SEPTICEMIA, UNSPECIFIED | |
| 4 | 29-32 Completed Weeks of Gestation | 765.25 | 29-30 COMPLETED WEEKS OF GESTATION | |
| 4 | 29-32 Completed Weeks of Gestation | 765.26 | 31-32 COMPLETED WEEKS OF GESTATION | |
| 5 | Less than 29 Completed Weeks of Gestation | 765.23 | 25-26 COMPLETED WEEKS OF GESTATION | |
| 5 | Less than 29 Completed Weeks of Gestation | 765.22 | 24 COMPLETED WEEKS OF GESTATION | |
| 5 | Less than 29 Completed Weeks of Gestation | 765.24 | 27-28 COMPLETED WEEKS OF GESTATION | |
| 5 | Less than 29 Completed Weeks of Gestation | 765.21 | LESS THAN 24 COMPLETED WEEKS OF GESTATION | |
| 6 | Respiratory Distress Syndrome and other Respiratory Issues/Aspiration | 770.12 | MECONIUM ASPIRATION WITH RESPIRATORY SYMPTOMS | |
| 6 | Respiratory Distress Syndrome and other Respiratory Issues/Aspiration | 770.14 | ASPIRATION OF CLEAR AMNIOTIC FLUID WITH RESPIRATORY SYMPTOMS | |
| 6 | Respiratory Distress Syndrome and other Respiratory Issues/Aspiration | 770.86 | ASPIRATION OF POSTNATAL STOMACH CONTENTS WITH RESPIRATORY SYMPTOMS | |
| 6 | Respiratory Distress Syndrome and other Respiratory Issues/Aspiration | 770.84 | RESPIRATORY FAILURE OF NEWBORN | |
| 6 | Respiratory Distress Syndrome and other Respiratory Issues/Aspiration | 770.89 | OTHER RESPIRATORY PROBLEMS AFTER BIRTH | |
| 6 | Respiratory Distress Syndrome and other Respiratory Issues/Aspiration | 769 | RESPIRATORY DISTRESS SYNDROME IN NEWBORN | |
| 6 | Respiratory Distress Syndrome and other Respiratory Issues/Aspiration | 770.18 | OTHER FETAL AND NEWBORN ASPIRATION WITH RESPIRATORY SYMPTOMS | |
| 6 | Respiratory Distress Syndrome and other Respiratory Issues/Aspiration | 770.81 | PRIMARY APNEA OF NEWBORN | |
| 6 | Respiratory Distress Syndrome and other Respiratory Issues/Aspiration | 770.82 | OTHER APNEA OF NEWBORN | |
| 6 | Respiratory Distress Syndrome and other Respiratory Issues/Aspiration | 770.83 | CYANOTIC ATTACKS OF NEWBORN | |
| 6 | Respiratory Distress Syndrome and other Respiratory Issues/Aspiration | 770.88 | HYPOXEMIA OF NEWBORN | |
| 6 | Respiratory Distress Syndrome and other Respiratory Issues/Aspiration | 770.11 | MECONIUM ASPIRATION WITHOUT RESPIRATORY SYMPTOMS | |
| 6 | Respiratory Distress Syndrome and other Respiratory Issues/Aspiration | 770.10 | FETAL AND NEWBORN ASPIRATION, UNSPECIFIED | |
| 6 | Respiratory Distress Syndrome and other Respiratory Issues/Aspiration | 770.87 | RESPIRATORY ARREST OF NEWBORN | |
| 6 | Respiratory Distress Syndrome and other Respiratory Issues/Aspiration | 770.15 | ASPIRATION OF BLOOD WITHOUT RESPIRATORY SYMPTOMS | |
| 7 | Device Implants | 996.63 | INFECTION AND INFLAMMATORY REACTION DUE TO NERVOUS SYSTEM DEVICE, IMPLANT, AND G | |
| 7 | Device Implants | 996.62 | INFECTION AND INFLAMMATORY REACTION DUE TO OTHER VASCULAR DEVICE, IMPLANT, AND G | |
| 7 | Device Implants | 996.75 | OTHER COMPLICATIONS DUE TO NERVOUS SYSTEM DEVICE, IMPLANT, AND GRAFT | |
| 7 | Device Implants | 996.74 | OTHER COMPLICATIONS DUE TO OTHER VASCULAR DEVICE, IMPLANT, AND GRAFT | |
| 7 | Device Implants | 996.79 | OTHER COMPLICATIONS DUE TO OTHER INTERNAL PROSTHETIC DEVICE, IMPLANT, AND GRAFT | |
| 7 | Device Implants | 996.69 | INFECTION AND INFLAMMATORY REACTION DUE TO OTHER INTERNAL PROSTHETIC DEVICE, IMPL | |
| 7 | Device Implants | 996.39 | MECHANICAL COMPLICATION OF OTHER GENITOURINARY DEVICE, IMPLANT, AND GRAFT | |
| 7 | Device Implants | 996.49 | OTHER MECHANICAL COMPLICATION OF OTHER INTERNAL ORTHOPEDIC DEVICE, IMPLANT, AND | |
| 7 | Device Implants | 996.67 | INFECTION AND INFLAMMATORY REACTION DUE TO OTHER INTERNAL ORTHOPEDIC DEVICE, IMP | |
| 7 | Device Implants | 996.59 | MECHANICAL COMPLICATION DUE TO OTHER IMPLANT AND INTERNAL DEVICE, NOT ELSEWHERE | |
| 7 | Device Implants | 996.72 | OTHER COMPLICATIONS DUE TO OTHER CARDIAC DEVICE, IMPLANT, AND GRAFT | |
| 7 | Device Implants | 996.30 | MECHANICAL COMPLICATION OF UNSPECIFIED GENITOURINARY DEVICE, | |

Appendix A
Risk Adjustment for TANF Under Age One Year

| Exhibit C TANF - Risk Marker Diagnosis Codes | | | |
|---|-------------------------------------|----------------|---|
| Risk Group (See Exhibit B) | Risk Marker Description | Diagnosis Code | ICD9 Description |
| 7 | Device Implants | 996.31 | MECHANICAL COMPLICATION DUE TO URETHRAL +INDWELLING+ CATHETER |
| 7 | Device Implants | 996.00 | MECHANICAL COMPLICATION OF UNSPECIFIED CARDIAC DEVICE, IMPLANT, AND GRAFT |
| 8 | Subdural or Subarachnoid Hemorrhage | 852.26 | SUBDURAL HEMORRHAGE FOLLOWING INJURY, WITHOUT MENTION OF |
| 8 | Subdural or Subarachnoid Hemorrhage | 800.26 | CLOSED FRACTURE OF VAULT OF SKULL WITH SUBARACHNOID, SUBDURAL, |
| 8 | Subdural or Subarachnoid Hemorrhage | 800.21 | CLOSED FRACTURE OF VAULT OF SKULL WITH SUBARACHNOID, SUBDURAL, |
| 8 | Subdural or Subarachnoid Hemorrhage | 852.01 | SUBARACHNOID HEMORRHAGE FOLLOWING INJURY, WITHOUT MENTION |
| 8 | Subdural or Subarachnoid Hemorrhage | 852.00 | SUBARACHNOID HEMORRHAGE FOLLOWING INJURY, WITHOUT MENTION |
| 8 | Subdural or Subarachnoid Hemorrhage | 852.20 | SUBDURAL HEMORRHAGE FOLLOWING INJURY, WITHOUT MENTION OF |
| 8 | Subdural or Subarachnoid Hemorrhage | 852.21 | SUBDURAL HEMORRHAGE FOLLOWING INJURY, WITHOUT MENTION OF |
| 8 | Subdural or Subarachnoid Hemorrhage | 800.20 | CLOSED FRACTURE OF VAULT OF SKULL WITH SUBARACHNOID, SUBDURAL, |
| 8 | Subdural or Subarachnoid Hemorrhage | 852.30 | SUBDURAL HEMORRHAGE FOLLOWING INJURY, WITH OPEN INTRACRANIAL |
| 8 | Subdural or Subarachnoid Hemorrhage | 801.21 | CLOSED FRACTURE OF BASE OF SKULL WITH SUBARACHNOID, SUBDURAL, |
| 8 | Subdural or Subarachnoid Hemorrhage | 852.29 | SUBDURAL HEMORRHAGE FOLLOWING INJURY, WITHOUT MENTION OF |
| 8 | Subdural or Subarachnoid Hemorrhage | 801.26 | CLOSED FRACTURE OF BASE OF SKULL WITH SUBARACHNOID, SUBDURAL, |
| 8 | Subdural or Subarachnoid Hemorrhage | 801.20 | CLOSED FRACTURE OF BASE OF SKULL WITH SUBARACHNOID, SUBDURAL, |
| 9 | Cardiac Congenital Disorders | 779.81 | NEONATAL BRADYCARDIA |
| 9 | Cardiac Congenital Disorders | 779.82 | NEONATAL TACHYCARDIA |
| 9 | Cardiac Congenital Disorders | 747.41 | TOTAL ANOMALOUS PULMONARY VENOUS CONNECTION |
| 9 | Cardiac Congenital Disorders | 745.19 | OTHER TRANSPOSITION OF GREAT VESSELS |
| 9 | Cardiac Congenital Disorders | 746.7 | HYPOPLASTIC LEFT HEART SYNDROME |
| 9 | Cardiac Congenital Disorders | 746.82 | COR TRIARTIATUM |
| 9 | Cardiac Congenital Disorders | 746.2 | EBSTEIN'S ANOMALY |
| 9 | Cardiac Congenital Disorders | 745.69 | OTHER ENDOCARDIAL CUSHION DEFECTS |
| 9 | Cardiac Congenital Disorders | 745.0 | COMMON TRUNCUS |
| 9 | Cardiac Congenital Disorders | 745.2 | TETRALOGY OF FALLOT |
| 9 | Cardiac Congenital Disorders | 747.11 | INTERRUPTION OF AORTIC ARCH |
| 9 | Cardiac Congenital Disorders | 746.85 | CORONARY ARTERY ANOMALY, CONGENITAL |
| 9 | Cardiac Congenital Disorders | 747.10 | COARCTATION OF AORTA (PREDUCTAL) (POSTDUCTAL) |
| 9 | Cardiac Congenital Disorders | 745.11 | DOUBLE OUTLET RIGHT VENTRICLE |
| 9 | Cardiac Congenital Disorders | 745.10 | COMPLETE TRANSPOSITION OF GREAT VESSELS |
| 9 | Cardiac Congenital Disorders | 747.83 | PERSISTENT FETAL CIRCULATION |
| 9 | Cardiac Congenital Disorders | 746.84 | OBSTRUCTIVE ANOMALIES OF HEART, CONGENITAL, NOT ELSEWHERE CLASSIFIED |
| 9 | Cardiac Congenital Disorders | 746.3 | CONGENITAL STENOSIS OF AORTIC VALVE |
| 9 | Cardiac Congenital Disorders | 746.5 | CONGENITAL MITRAL STENOSIS |
| 9 | Cardiac Congenital Disorders | 746.00 | CONGENITAL PULMONARY VALVE ANOMALY, UNSPECIFIED |
| 9 | Cardiac Congenital Disorders | 746.86 | CONGENITAL HEART BLOCK |
| 9 | Cardiac Congenital Disorders | 746.02 | STENOSIS OF PULMONARY VALVE, CONGENITAL |
| 9 | Cardiac Congenital Disorders | 746.6 | CONGENITAL MITRAL INSUFFICIENCY |

Appendix A
Risk Adjustment for TANF Under Age One Year

| Exhibit C TANF < Risk Marker Diagnosis Codes | | | |
|---|---|----------------|---|
| Risk Group (See Exhibit B) | Risk Marker Description | Diagnosis Code | ICD9 Description |
| 9 | Cardiac Congenital Disorders | 745.3 | COMMON VENTRICLE |
| 9 | Cardiac Congenital Disorders | 747.42 | PARTIAL ANOMALOUS PULMONARY VENOUS CONNECTION |
| 9 | Cardiac Congenital Disorders | 746.01 | ATRESIA OF PULMONARY VALVE, CONGENITAL |
| 9 | Cardiac Congenital Disorders | 427.0 | PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA |
| 9 | Cardiac Congenital Disorders | 747.40 | ANOMALY OF GREAT VEINS, CONGENITAL, UNSPECIFIED |
| 9 | Cardiac Congenital Disorders | 746.1 | TRICUSPID ATRESIA AND STENOSIS, CONGENITAL |
| 9 | Cardiac Congenital Disorders | 426.7 | ANOMALOUS ATRIOVENTRICULAR EXCITATION |
| 9 | Cardiac Congenital Disorders | 745.4 | VENTRICULAR SEPTAL DEFECT |
| 9 | Cardiac Congenital Disorders | 747.21 | CONGENITAL ANOMALIES OF AORTIC ARCH |
| 9 | Cardiac Congenital Disorders | 746.89 | OTHER SPECIFIED CONGENITAL ANOMALIES OF HEART |
| 9 | Cardiac Congenital Disorders | 747.49 | OTHER ANOMALIES OF GREAT VEINS |
| 9 | Cardiac Congenital Disorders | 746.9 | UNSPECIFIED CONGENITAL ANOMALY OF HEART |
| 9 | Cardiac Congenital Disorders | 747.3 | ANOMALIES OF PULMONARY ARTERY, CONGENITAL |
| 9 | Cardiac Congenital Disorders | 746.87 | MALPOSITION OF HEART AND CARDIAC APEX |
| 9 | Cardiac Congenital Disorders | 745.60 | ENDOCARDIAL CUSHION DEFECT, UNSPECIFIED TYPE |
| 9 | Cardiac Congenital Disorders | 426.9 | CONDUCTION DISORDER, UNSPECIFIED |
| 9 | Cardiac Congenital Disorders | 747.0 | PATENT DUCTUS ARTERIOSUS |
| 9 | Cardiac Congenital Disorders | 746.4 | CONGENITAL INSUFFICIENCY OF AORTIC VALVE |
| 9 | Cardiac Congenital Disorders | 747.22 | CONGENITAL ATRESIA AND STENOSIS OF AORTA |
| 9 | Cardiac Congenital Disorders | 458.9 | HYPOTENSION, UNSPECIFIED |
| 9 | Cardiac Congenital Disorders | 746.83 | INFUNDIBULAR PULMONIC STENOSIS, CONGENITAL |
| 9 | Cardiac Congenital Disorders | 745.5 | OSTIUM SECUNDUM TYPE ATRIAL SEPTAL DEFECT |
| 9 | Cardiac Congenital Disorders | 747.29 | OTHER CONGENITAL ANOMALIES OF AORTA |
| 9 | Cardiac Congenital Disorders | 429.4 | FUNCTIONAL DISTURBANCES FOLLOWING CARDIAC SURGERY |
| 9 | Cardiac Congenital Disorders | 745.12 | CORRECTED TRANSPOSITION OF GREAT VESSELS |
| 9 | Cardiac Congenital Disorders | 425.3 | ENDOCARDIAL FIBROELASTOSIS |
| 9 | Cardiac Congenital Disorders | 745.8 | OTHER BULBUS CORDIS ANOMALIES AND ANOMALIES OF CARDIAC SEPTAL |
| 9 | Cardiac Congenital Disorders | 426.89 | OTHER SPECIFIED CONDUCTION DISORDERS |
| 9 | Cardiac Congenital Disorders | 429.3 | CARDIOMEGALY |
| 9 | Cardiac Congenital Disorders | 425.1 | HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY |
| 9 | Cardiac Congenital Disorders | 747.5 | ABSENCE OR HYPOPLASIA OF UMBILICAL ARTERY |
| 9 | Cardiac Congenital Disorders | 746.09 | OTHER CONGENITAL ANOMALIES OF PULMONARY VALVE |
| 9 | Cardiac Congenital Disorders | 746.81 | SUBAORTIC STENOSIS, CONGENITAL |
| 9 | Cardiac Congenital Disorders | 747.89 | OTHER SPECIFIED CONGENITAL ANOMALIES OF CIRCULATORY SYSTEM |
| 10 | Central Nervous System Congenital Disorders | 747.81 | ANOMALIES OF CEREBROVASCULAR SYSTEM, CONGENITAL |
| 10 | Central Nervous System Congenital Disorders | 741.03 | SPINA BIFIDA WITH HYDROCEPHALUS, LUMBAR REGION |
| 10 | Central Nervous System Congenital Disorders | 741.93 | SPINA BIFIDA, WITHOUT MENTION OF HYDROCEPHALUS, LUMBAR REGION |
| 10 | Central Nervous System Congenital Disorders | 742.4 | OTHER SPECIFIED CONGENITAL ANOMALIES OF BRAIN |

Appendix A
Risk Adjustment for TANF Under Age One Year

| Exhibit C TANF < Risk Marker Diagnosis Codes | | | |
|---|--|----------------|---|
| Risk Group (See Exhibit B) | Risk Marker Description | Diagnosis Code | ICD9 Description |
| 10 | Central Nervous System Congenital Disorders | 741.00 | SPINA BIFIDA WITH HYDROCEPHALUS, UNSPECIFIED REGION |
| 10 | Central Nervous System Congenital Disorders | 742.3 | CONGENITAL HYDROCEPHALUS |
| 10 | Central Nervous System Congenital Disorders | 742.0 | ENCEPHALOCELE |
| 10 | Central Nervous System Congenital Disorders | 742.2 | CONGENITAL REDUCTION DEFORMITIES OF BRAIN |
| 10 | Central Nervous System Congenital Disorders | 741.90 | SPINA BIFIDA, WITHOUT MENTION OF HYDROCEPHALUS, UNSPECIFIED REGION |
| 10 | Central Nervous System Congenital Disorders | 742.59 | OTHER SPECIFIED CONGENITAL ANOMALIES OF SPINAL |
| 10 | Central Nervous System Congenital Disorders | 348.0 | CEREBRAL CYSTS |
| 10 | Central Nervous System Congenital Disorders | 741.02 | SPINA BIFIDA WITH HYDROCEPHALUS, DORSAL +THORACIC+ REGION |
| 10 | Central Nervous System Congenital Disorders | 348.39 | OTHER ENCEPHALOPATHY |
| 10 | Central Nervous System Congenital Disorders | 333.1 | ESSENTIAL AND OTHER SPECIFIED FORMS OF TREMOR |
| 10 | Central Nervous System Congenital Disorders | 348.30 | ENCEPHALOPATHY, UNSPECIFIED |
| 10 | Central Nervous System Congenital Disorders | 348.5 | CEREBRAL EDEMA |
| 10 | Central Nervous System Congenital Disorders | 759.5 | TUBEROUS SCLEROSIS |
| 10 | Central Nervous System Congenital Disorders | 348.1 | ANOXIC BRAIN DAMAGE |
| 10 | Central Nervous System Congenital Disorders | 742.1 | MICROCEPHALUS |
| 10 | Central Nervous System Congenital Disorders | 228.02 | HEMANGIOMA OF INTRACRANIAL STRUCTURES |
| 10 | Central Nervous System Congenital Disorders | 348.4 | COMPRESSION OF BRAIN |
| 10 | Central Nervous System Congenital Disorders | 742.51 | DIASTEMATOMYELIA |
| 10 | Central Nervous System Congenital Disorders | 742.9 | UNSPECIFIED CONGENITAL ANOMALY OF BRAIN, SPINA |
| 10 | Central Nervous System Congenital Disorders | 741.92 | SPINA BIFIDA, WITHOUT MENTION OF HYDROCEPHALUS, DORSAL (THORACIC) REGION |
| 10 | Central Nervous System Congenital Disorders | 740.0 | ANENCEPHALUS |
| 10 | Central Nervous System Congenital Disorders | 742.8 | OTHER SPECIFIED CONGENITAL ANOMALIES OF NERVOU |
| 11 | Congenital Anomalies of Intestines & Abdomen | 756.70 | CONGENITAL ANOMALY OF ABDOMINAL WALL, UNSPECIFIED |
| 11 | Congenital Anomalies of Intestines & Abdomen | 756.79 | OTHER CONGENITAL ANOMALIES OF ABDOMINAL WALL |
| 11 | Congenital Anomalies of Intestines & Abdomen | 751.1 | ATRESIA AND STENOSIS OF SMALL INTESTINE, CONGENITAL |
| 11 | Congenital Anomalies of Intestines & Abdomen | 751.3 | HIRSCHSPRUNG'S DISEASE AND OTHER CONGENITAL FUNCTIONAL |
| 11 | Congenital Anomalies of Intestines & Abdomen | 756.71 | PRUNE BELLY SYNDROME |
| 11 | Congenital Anomalies of Intestines & Abdomen | 751.5 | OTHER CONGENITAL ANOMALIES OF INTESTINE |
| 11 | Congenital Anomalies of Intestines & Abdomen | 751.2 | ATRESIA AND STENOSIS OF LARGE INTESTINE, RECTUM, AND ANAL CANAL, CONGENITAL |
| 11 | Congenital Anomalies of Intestines & Abdomen | 751.4 | ANOMALIES OF INTESTINAL FIXATION, CONGENITAL |
| 11 | Congenital Anomalies of Intestines & Abdomen | 751.0 | MECKEL'S DIVERTICULUM |
| 11 | Congenital Anomalies of Intestines & Abdomen | 759.6 | OTHER CONGENITAL HAMARTOSES, NOT ELSEWHERE CLASSIFIED |
| 11 | Congenital Anomalies of Intestines & Abdomen | 751.9 | UNSPECIFIED CONGENITAL ANOMALY OF DIGESTIVE SYSTEM |
| 11 | Congenital Anomalies of Intestines & Abdomen | 751.8 | OTHER SPECIFIED CONGENITAL ANOMALIES OF DIGESTIVE SYSTEM |
| 11 | Congenital Anomalies of Intestines & Abdomen | 759.3 | SITUS INVERSUS |